These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37266140)

  • 21. Non-invasive screening using ventilatory gas analysis to distinguish between chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.
    Akizuki M; Sugimura K; Aoki T; Kakihana T; Tatebe S; Yamamoto S; Sato H; Satoh K; Shimokawa H; Kohzuki M
    Respirology; 2020 Apr; 25(4):427-434. PubMed ID: 31261445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The oxygen kinetic effect of inhaled iloprost in pulmonary artery hypertension and chronic thromboembolic pulmonary hypertension].
    Cui N; Yang YH; Xie WM; Ma ZH; Luo L; Wang C
    Zhonghua Jie He He Hu Xi Za Zhi; 2009 Jul; 32(7):522-6. PubMed ID: 19954007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension.
    Godinas L; Sattler C; Lau EM; Jaïs X; Taniguchi Y; Jevnikar M; Weatherald J; Sitbon O; Savale L; Montani D; Simonneau G; Humbert M; Laveneziana P; Garcia G
    J Heart Lung Transplant; 2017 Nov; 36(11):1234-1242. PubMed ID: 28666570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.
    Sulica R; Fenton R; Cefali F
    Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From Health-Related Quality of Life (HRQoL) of Patients with Pulmonary Hypertension to Patient Experience with the Care Received: Should We Be More Aware of Current Patient Needs?
    Martínez Meñaca A; Blanco Vich I; López Meseguer M; López Reyes R; Bedate Díaz P; Elías Hernández T; Fernández-Cuesta Peñafiel I; Fernández G; Álvez Liste A; Escribano Subías P
    Adv Ther; 2021 Apr; 38(4):1860-1875. PubMed ID: 33675523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anxiety and Depression in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension after the Removal of COVID-19 Pandemic Restrictions.
    Wieteska-Miłek M; Witowicz A; Szmit S; Florczyk M; Peller M; Dzienisiewicz M; Kurzyna M
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930062
    [No Abstract]   [Full Text] [Related]  

  • 28. [Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry].
    Chazova IE; Valieva ZS; Nakonechnikov SN; Taran IN; Martynyuk TV
    Ter Arkh; 2019 Sep; 91(9):77-87. PubMed ID: 32598818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-COVID-19 Symptoms 2 Years After SARS-CoV-2 Infection Among Hospitalized vs Nonhospitalized Patients.
    Fernández-de-Las-Peñas C; Rodríguez-Jiménez J; Cancela-Cilleruelo I; Guerrero-Peral A; Martín-Guerrero JD; García-Azorín D; Cornejo-Mazzuchelli A; Hernández-Barrera V; Pellicer-Valero OJ
    JAMA Netw Open; 2022 Nov; 5(11):e2242106. PubMed ID: 36378309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Humbert M; Farber HW; Ghofrani HA; Benza RL; Busse D; Meier C; Hoeper MM
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30923187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and Instrumental Characteristics of Newly Diagnosed Patients with Various Forms of Pulmonary Hypertension according to the Russian National Registry.
    Chazova IY; Martynyuk TV; Valieva ZS; Gratsianskaya SY; Aleevskaya AM; Zorin AV; Nakonechnikov SN
    Biomed Res Int; 2020; 2020():6836973. PubMed ID: 32626754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Characteristics of patients with chronic thromboembolic pulmonary hypertension according to the Russian National Registry].
    Valieva ZS; Martynyuk TV; Nakonechnikov SN; Chazova IE
    Ter Arkh; 2021 Sep; 93(9):1058-1065. PubMed ID: 36286865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac sequelae after COVID-19: Results of a 1-year follow-up study with echocardiography and biomarkers.
    Matejova G; Radvan M; Bartecku E; Kamenik M; Koc L; Horinkova J; Sykorova L; Stepanova R; Kala P
    Front Cardiovasc Med; 2022; 9():1067943. PubMed ID: 36620643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Depression, anxiety and psychological distress in patients with pulmonary hypertension: a mixed-methods study.
    Takita Y; Takeda Y; Fujisawa D; Kataoka M; Kawakami T; Doorenbos AZ
    BMJ Open Respir Res; 2021 Apr; 8(1):. PubMed ID: 33926959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent progress in the diagnosis and management of chronic thromboembolic pulmonary hypertension.
    Tanabe N; Sugiura T; Tatsumi K
    Respir Investig; 2013 Sep; 51(3):134-46. PubMed ID: 23978639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension.
    Burudpakdee C; Shah A; Joish VN; Divers C; Yaldo A
    Am Health Drug Benefits; 2014 Dec; 7(9):479-87. PubMed ID: 25610527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
    Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
    Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. From acute SARS-CoV-2 infection to pulmonary hypertension.
    Eroume À Egom E; Shiwani HA; Nouthe B
    Front Physiol; 2022; 13():1023758. PubMed ID: 36601347
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.